KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial.Lancet Gastroenterol HepatolPMID 39151436无 PMCID2024-Oct0.93干预为非药物单独策略,未满足药物干预要求。待处理
Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial.Clin TherPMID 39153911无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons.J Comp Eff ResPMID 39158844PMC114283432024-Oct0.98未发现恶性肿瘤人群证据。待处理
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.Cancer Commun (Lond)PMID 39161079PMC114837112024-Oct0.90The record describes a Phase III randomized trial in oncology (esophageal squamous cell carcinoma) with human participants and primary/secondary time-to-event endpoints (OS, PFS). It reports original results. However, the intervention is solely concurrent chemoradiotherapy where the comparisons are between different radiation doses and fields, with no evidence of a specific drug-containing intervention arm being tested against a control. The intervention is a radiation regimen variation, not a drug trial.待处理
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.J Clin OncolPMID 39167741无 PMCID2024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.Dokl Biochem BiophysPMID 39196526无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial.Thorac CancerPMID 39199003PMC114449242024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico.Leuk ResPMID 39214018无 PMCID2024-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).Mult Scler Relat DisordPMID 39217809无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.Cancer Commun (Lond)PMID 39221992PMC114835532024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study.Curr Med Res OpinPMID 39235266无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials.DrugsPMID 39240530PMC115128912024-Oct0.98未发现恶性肿瘤人群证据。待处理
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study.Lancet OncolPMID 39245060无 PMCID2024-Oct0.95The study is a randomized, phase 3, original result report in human oncology. However, it is excluded because the primary endpoint is a pain response at a fixed time point (not a time-to-event outcome like OS, PFS, etc.) and the intervention is radiotherapy (non-drug).待处理
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial.Lancet Respir MedPMID 39265599无 PMCID2024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.Lancet Respir MedPMID 39265600无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet HaematolPMID 39265613无 PMCID2024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.Lancet Respir MedPMID 39270696无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.Lung CancerPMID 39303400无 PMCID2024-Oct0.95The report is an original, formal result of a randomized Phase III oncology trial with a drug intervention. However, it is excluded because its primary endpoints are patient-reported outcomes and quality of life measures, not the required time-to-event efficacy endpoints (e.g., OS, PFS). The abstract does not report Kaplan-Meier curves or hazard ratios for survival or progression endpoints.待处理
Temazepam or Melatonin Versus Placebo for the Treatment of Insomnia in Advanced Cancer: A Three-Arm, Double-Blind, Phase III, Multicenter, Randomized Clinical Trial.J Palliat MedPMID 39304187无 PMCID2024-Oct0.80The study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original results, but the primary endpoint is a patient-reported symptom score (ISI), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).待处理
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial.Lancet NeurolPMID 39304240无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.Lung CancerPMID 39306923无 PMCID2024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.Health Technol AssessPMID 39364774PMC114749522024-Oct0.98未发现恶性肿瘤人群证据。待处理
Clinical effectiveness of DREAMS START (Dementia Related Manual for Sleep; Strategies for Relatives) versus usual care for people with dementia and their carers: a single-masked, phase 3, parallel-arm, superiority randomised controlled trial.Lancet Healthy LongevPMID 39366393无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
A cost-effectiveness analysis of stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the management of stage 1 non-small-cell lung cancer: Results from the TROG 09.02 CHISEL study.J Med Imaging Radiat OncolPMID 39382099无 PMCID2024-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors.ESMO OpenPMID 39389003PMC116934292024-Oct0.95The study is a randomized, phase III trial in oncology with drug intervention, but its primary endpoints are not time-to-event efficacy outcomes (e.g., OS, PFS). It focuses on biomarker prediction and changes in body composition, metabolism, and quality of life, which do not meet the inclusion criteria for a Kaplan-Meier digitization cohort.待处理
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.Health Technol AssessPMID 39397484PMC114919872024-Oct0.98未发现恶性肿瘤人群证据。待处理
Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial).ESMO OpenPMID 39461773PMC115495192024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial.ESMO OpenPMID 39461775PMC115495302024-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis.CutisPMID 39621574无 PMCID2024-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).Eur Respir JPMID 39326918PMC114472862024-Oct0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 39288781PMC115125882024-Sep-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.LancetPMID 39293462PMC121216142024-Sep-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study.Clin Infect DisPMID 38985561PMC114262792024-Sep-260.98未发现恶性肿瘤人群证据。待处理
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection.N Engl J MedPMID 39321361无 PMCID2024-Sep-260.98未发现恶性肿瘤人群证据。待处理
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.N Engl J MedPMID 39321362无 PMCID2024-Sep-260.95The study is a Phase 3 clinical trial of gene therapy for Hemophilia B, which is not an oncology condition. It is non-randomized, lacks a drug-containing intervention (gene therapy is not a conventional drug), and the primary endpoint is annualized bleeding rate, not a time-to-event efficacy endpoint like OS, PFS, etc. Therefore, it does not meet the inclusion criteria for an oncology Kaplan-Meier digitization cohort.待处理
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.Blood AdvPMID 39058951PMC114165822024-Sep-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.RMD OpenPMID 39313302PMC114185372024-Sep-230.95The study is a Phase 3 randomized trial of a drug intervention in psoriatic arthritis, which is not an oncology condition. The efficacy endpoints are patient-reported outcomes and health-related quality of life, not time-to-event efficacy endpoints such as OS, PFS, DFS, EFS, RFS, TTP, or those analyzed via Kaplan-Meier or HR.待处理
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.LancetPMID 39270686无 PMCID2024-Sep-210.98未发现恶性肿瘤人群证据。待处理
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.J Clin OncolPMID 39102628无 PMCID2024-Sep-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.Signal Transduct Target TherPMID 39300077PMC114129702024-Sep-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Does stereotactic thrombolysis with alteplase for intracerebral haemorrhage alter intraventricular haematoma volume? A secondary analysis of the MISTIE-III trial.J Neurol Neurosurg PsychiatryPMID 38670789PMC120543982024-Sep-170.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.VaccinePMID 38853036无 PMCID2024-Sep-170.98未发现恶性肿瘤人群证据。待处理
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.JAMAPMID 39037800PMC112640752024-Sep-170.98未发现恶性肿瘤人群证据。待处理
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.J Am Coll CardiolPMID 39260929无 PMCID2024-Sep-170.98未发现恶性肿瘤人群证据。待处理
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.MedPMID 38870931无 PMCID2024-Sep-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.MedPMID 38870932无 PMCID2024-Sep-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer ResPMID 38990098PMC113935392024-Sep-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.BMC CancerPMID 39272058PMC113952172024-Sep-130.85The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original results. However, it is excluded because the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoint is 'duration of grade 3/4 neutropenia,' a continuous variable, and no time-to-event analysis (Kaplan-Meier, HR) is reported.待处理
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.N Engl J MedPMID 38820078无 PMCID2024-Sep-120.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial.Radiat OncolPMID 39267085PMC113956422024-Sep-120.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理